Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
:HUMA
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.76 - $9.97
Previous CloseN/A
Volume1.64M
Average Volume (3M)3.12M
Market Cap
$301.19M
Enterprise Value$646.13M
Total Cash (Recent Filing)$39.93M
Total Debt (Recent Filing)$28.86M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
May 09, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding153,668,490
10 Day Avg. Volume5,004,075
30 Day Avg. Volume3,121,691
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap2.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.44
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$14.00Price Target Upside614.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
CommercializationHUMA is beginning its commercial era now that its first indication of extremity vascular trauma has been approved.
Market ExpansionThe recent financing provides HUMA with capital to support continued expansion of the US Symvess launch and pipeline.
Bears Say
Safety ConcernsHUMA stock pressure is overdone as a recent news article discussing Symvess' safety profile is 'old news' for investors and clinicians.
Stock ValuationPT moves to $5 (~8x 2027E sales) from $7.50, to reflect the recent contraction in small-cap valuations and the new share count.
---
Ownership Overview
5.94% Insiders
6.16% Mutual Funds
5.90% Other Institutional Investors
71.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.76 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $301.19M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is May 09, 2025 which is in 40 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Mar 28, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.09.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.22.
How many shares outstanding does Humacyte have?
Humacyte has 153,668,490 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -2.488%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
---
Humacyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (614.29% Upside)
$14.00 (614.29% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.97%
12-Months-Change
Fundamentals
Return on Equity
239.90%
Trailing 12-Months
Asset Growth
-23.18%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. (HUMA) is a biotechnology company focused on developing and commercializing bioengineered human tissues and organs that are designed to treat a variety of diseases and conditions. The company primarily operates within the regenerative medicine sector, aiming to address critical needs in vascular and organ replacement. Humacyte's core product is its investigational Human Acellular Vessel (HAV), which is being explored for use in vascular surgeries and treatments for patients with end-stage renal disease, peripheral arterial disease, and other vascular conditions.
---
HUMA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$14.00
▲(614.29% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
-11.53%
reiterated a buy rating 2 days ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of -11.53% per trade.
---